Nitrate ( DrugBank: Nitrate )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
58	肥大型心筋症	2
67	多発性嚢胞腎	1
113	筋ジストロフィー	3
299	嚢胞性線維症	4

58. 肥大型心筋症

臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03832660 (ClinicalTrials.gov)	May 3, 2019	1/2/2019	Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy	Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Behavioral: Lifestyle;Drug: Sacubitril/Valsartan	Newcastle University	Azienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of Belgrade	Completed	18 Years	70 Years	All	168	Phase 2	Germany;Italy;Serbia;United Kingdom
2	NCT03251287 (ClinicalTrials.gov)	November 2017	11/8/2017	Nitrite in Hypertrophic Cardiomyopathy (HCM) Study	Mechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic Cardiomyopathy	Cardiomyopathy, Hypertrophic	Drug: Sodium Nitrate;Drug: Placebo;Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;Diagnostic Test: Exercise Stress Transthoracic Echocardiogram	University of East Anglia	Norfolk and Norwich University Hospitals NHS Foundation Trust;British Medical Research Council	Recruiting	18 Years	80 Years	All	18	Phase 1	United Kingdom

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05401409 (ClinicalTrials.gov)	May 5, 2022	27/5/2022	Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease	Double-Blind, Randomised Placebo-Controlled Study to Determine the Effect of Beetroot Juice on Reducing Blood Pressure in Hypertensive Adults With Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney;Hypertension;Endothelial Dysfunction	Dietary Supplement: Beetroot juice;Dietary Supplement: Nitrate-depleted beetroot juice	Western Sydney Local Health District	Westmead Institute for Medical Research	Recruiting	18 Years	70 Years	All	60	N/A	Australia

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02434627 (ClinicalTrials.gov)	June 2015	28/4/2015	Sodium Nitrate for Muscular Dystrophy	Sodium Nitrate for Muscular Dystrophy	Becker Muscular Dystrophy	Drug: Sodium Nitrate	Cedars-Sinai Medical Center	NULL	Completed	15 Years	45 Years	Male	5	Phase 1	United States
2	NCT02147639 (ClinicalTrials.gov)	October 2013	25/3/2014	Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy		Becker Muscular Dystrophy	Dietary Supplement: Sodium Nitrate;Dietary Supplement: Sodium Nitrate - double dose;Dietary Supplement: Placebo;Procedure: Increased exercise intensity	Cedars-Sinai Medical Center	NULL	Completed	15 Years	45 Years	Male	19	Phase 2/Phase 3	United States
3	NCT02847975 (ClinicalTrials.gov)	October 2013	30/4/2014	Sodium Nitrate to Improve Blood Flow	Sodium Nitrate to Improve Blood Flow	Becker Muscular Dystrophy	Dietary Supplement: Sodium nitrate	Cedars-Sinai Medical Center	NULL	Completed	15 Years	55 Years	Male	11	Phase 1	United States

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04294043 (ClinicalTrials.gov)	June 17, 2021	1/3/2020	IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)	A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study)	Nontuberculous Mycobacterium Infection	Drug: Gallium nitrate	Chris Goss	Cystic Fibrosis Foundation	Recruiting	18 Years	N/A	All	40	Phase 1	United States
2	NCT02354859 (ClinicalTrials.gov)	March 2016	30/7/2014	A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)	A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)	Cystic Fibrosis	Drug: Gallium nitrate;Drug: Normal Saline	University of Washington	Cystic Fibrosis Foundation	Completed	18 Years	N/A	All	119	Phase 2	United States
3	NCT02310789 (ClinicalTrials.gov)	July 31, 2015	3/9/2014	(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?	(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil	Cystic Fibrosis	Drug: Ivacaftor;Drug: ß-Adrenergic cocktail;Drug: Pilocarpine Nitrate 5%;Device: Macroduct sweat stimulator	Richard Barry Moss	NULL	Completed	18 Years	N/A	All	8	N/A	United States
4	NCT01093521 (ClinicalTrials.gov)	April 2010	24/3/2010	A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients	A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients	Cystic Fibrosis	Drug: 100 mg/m2 dose;Drug: 200 mg/m2 dose	University of Washington	Cystic Fibrosis Foundation	Completed	18 Years	55 Years	All	20	Phase 1	United States

先頭へ